Press Release
Jun 29, 2022
Contact: Chris Martin | IASLC Media Relations | cmartin@davidjamesgroup.com
Release Date: June 29, 2021
Journal of Thoracic Oncology Impact Factor Surpasses 20
Growth Represents the Quality of Research and the Speed to Publication for the IASLC’s Official Journal
DENVER – The International Association for the Study of Lung Cancer (IASLC) today reported that its main cancer journal, the Journal of Thoracic Oncology (JTO), improved its Impact Factor from 15.069 in 2020 to 20.121 in 2021. The JTO, the official journal of the IASLC, now ranks 13th out of all 245 oncology journals and fourth out of all 65 respiratory system journals.
Impact Factors are measured by calculating the number of times journal articles in the two preceding years are cited in a current year. Thus, the Impact Factor for 2021 is the number of times articles published in 2019 and 2020 are cited in 2021. The higher the Impact Factor, the more highly ranked the journal. Journal citation reports are issued by Clarivate Analytics.
The JTO is the primary educational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Emphasizing a multidisciplinary approach, the JTO includes original research, review articles and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists and basic scientists with a special interest in thoracic oncology.
“The Impact Factor of JTO has quadrupled from 5.040 in 2015 to 20.121 in 2021. This is a testament to the exemplary work of our editorial board and our editorial manager as well as the support of IASLC – its executives, office staff, membership and above all our reviewers, readers and authors,” said Editor-in-Chief, Alex A. Adjei, M.D. “JTO will continue its emphasis on multidisciplinary research to serve the broad community working in thoracic oncology.”
The JTO continues to have a quick turn-around time of 5.6 days to initial decision, and an average of 13.7 days for revisions, a fast-track category, publish on acceptance (within 5 days) and promotion of select articles via social media and press releases. Authors can promote their own research by utilizing Elsevier enhancements such as Sharelink. In 2020, IASLC also launched an open access journal, JTO Clinical and Research Reports, to expand their ability to publish quality research in thoracic oncology.
To submit a manuscript or to learn more about the JTO, please visit jto.org. Once there, readers can peruse current in-press articles, collections of lung cancer staging and pathology articles and the freely available Editor’s Choice articles. The full contents of the JTO are a free benefit for IASLC members.
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the JTO
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.